Scribd
Upload
310 views36 pages

CIDP: A Guide for Clinicians

CIDP is a rare autoimmune disorder characterized by chronic, progressive peripheral neuropathy. It is distinguished from Guillain-Barré syndrome by its polyphasic time course and response to corticosteroid therapy. CIDP can cause proximal weakness, large fiber sensory loss, and generalized hypo- or areflexia. Diagnosis involves confirming progressive symmetric weakness and sensory dysfunction over 2 months through clinical features and electrodiagnostic testing while excluding other conditions. Treatment typically involves immune therapies such as corticosteroids, plasma exchange, and intravenous immunoglobulin which have shown short-term efficacy in the majority of cases.

Uploaded by

Safitri Muhlisa
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
310 views36 pages

CIDP: A Guide for Clinicians

CIDP is a rare autoimmune disorder characterized by chronic, progressive peripheral neuropathy. It is distinguished from Guillain-Barré syndrome by its polyphasic time course and response to corticosteroid therapy. CIDP can cause proximal weakness, large fiber sensory loss, and generalized hypo- or areflexia. Diagnosis involves confirming progressive symmetric weakness and sensory dysfunction over 2 months through clinical features and electrodiagnostic testing while excluding other conditions. Treatment typically involves immune therapies such as corticosteroids, plasma exchange, and intravenous immunoglobulin which have shown short-term efficacy in the majority of cases.

Uploaded by

Safitri Muhlisa
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd

CIDP

(Chronic Inflammatory Demyelinating Polyneuropathy)


Introduction
• Chronic Inflammatory Denyelinating Polyneuropathy (CIDP) is
a chronic, acquired, immune-mediated condition affecting the
peripheral nervous system
• CIDP is rare autoimmune disorder characterized by
progressive peripheral neuropathy
• Guidelines for the diagnosis and treatment of CIDP have been
developed, the large variety of clinical and
electrophysiological variants, associated systemuc conditions,
and lack of sustained improvement with standard treatments
in up to one third of cases provide challenges to the clinician
in practice
• It is treatable in the majority of the cases
• Numerous clinical trials have establish the short-term efficacy
of immune therapies such as corticosteroids, plasma exchange
(PE), and introvebous immune globulin (IVIg)
CIDP vs GBS
• CIDP is distinguish from
acute inflammatory CIDP GBS
demyelinating Time course Polyphasic Monophasic
polyradiculopathy (remission
(AIDP), the most and relap)
common form of Antibody Unclear Identified
Guillain-Barre Syndrome
(GBS), by time course Severity of clinical Less Severe
and steroid symptom
responsiveness Response to Yes No
• CIDP typically responds steroid
to corticosteroid therapy,
whereas AIDP does not
Clinical features of CIPD (Joint Task
Force of The EFNS And PNS, 2010)

Progressive symmetrical or asymmetrical polyradiculopathy

Relapsing or progressive course >2 months

Proximal weakness usually prominent

Large fiber sensory loss in the distal limbs (vibration and joint position sense)

Generalized hypo-reflex or areflex


Clinical & Electrodiagnostic Criteria
Inclusion Criteria
Exclusion Criteria
Typical CIDP Atypical CIDP
- Chronic progressive, -Predominantly - Infection, drug/ toxin
stepwise, or distal - Hereditary
recurrent symmetric - Asymmetric - Sphincter distrubance
prox & distal - Focal - Diagnosis of MMN
weakness & sensory - Pure motor - IgM monoclonal gammanopathy
dysfunction all - Pure Sensory - Other demyelinating neruopathy
extremities
- ±2 months durations
- Cranial nerve
affected
- Tendon reflexes
absent/ reduced in
all extremities
Thank You

You might also like